ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Context: There is limited data to characterize treatment patterns of biologics for severe asthma across regions.

Aims: Describe biologic treatment patterns within a severe asthma population across 3 geographical regions.

Methods: Descriptive analysis of treatment patterns of biologics for asthma were conducted using US Optum Clinformatics® Data-Mart database (2017-2021), JMDC database-Japan (2017-2021), and Evidera LiveTracker® from Europe (Germany, France, Italy, Spain, UK), with a retrospective chart review (1992-2022).

Results: A total of 4502, 778, and 1753 patients treated with biologics for asthma was identified in the US, Japan, and Europe, respectively. Anti-IL-5 was the most prescribed biologic: 43% (US), 39% (Japan) and 48% (EU); followed by anti-IgE in the US (31%) and EU (37%), and anti-IL-4/13 in Japan (33%). Switches from index biologic to a 2^nd line biologic were infrequent. Any discontinuation from index biologic for aIL-5 was 63% (US), 28% (Japan) and 3% (EU), aIgE was 70% (US), 50% (Japan) and 10% (EU), aIL-4/13 was 81% (US), 45% (Japan) and 5% (EU).

Conclusions: Differences between biologic treatment patterns across biologics and regions regarding initiation, switches, and discontinuation of therapy for patients with severe asthma were observed.

Funding: GSK: 218238, 219355, 214680

Abstract

#{title}